What are the recommended antiemetic drugs and dosing regimens for adults and children, including alternatives for refractory or chemotherapy‑induced nausea?

Antiemetic Medications: Recommended Drugs and Dosing

For chemotherapy-induced nausea and vomiting, use a 5-HT3 receptor antagonist (ondansetron 16-24 mg PO or granisetron 1-2 mg PO) combined with dexamethasone 20 mg PO before highly emetogenic chemotherapy, and add an NK1 receptor antagonist (aprepitant 125 mg day 1, then 80 mg days 2-3) for optimal control. 1, 2

Chemotherapy-Induced Nausea and Vomiting (CINV)

Highly Emetogenic Chemotherapy (HEC)

Acute Phase (Day 1):

• 5-HT3 antagonist (choose one):

  • Ondansetron 16-24 mg PO 3
  • Granisetron 1-2 mg PO or 1 mg IV 3
  • Palonosetron 0.25 mg IV 3
  • Dolasetron 100 mg PO 3
  • Tropisetron 5 mg PO 3

• PLUS Dexamethasone 20 mg PO/IV 4, 3

• PLUS NK1 antagonist (choose one):

  • Aprepitant 125 mg PO day 1, then 80 mg days 2-3 3
  • Fosaprepitant (IV formulation)
  • Rolapitant (single dose, do not repeat within 2 weeks) 5
  • Netupitant (available as combination with palonosetron) 5

Delayed Phase (Days 2-5):

• Dexamethasone 4-8 mg PO BID for 2-4 days 4, 3
• Continue NK1 antagonist per schedule 3

Important Note: When combining aprepitant with dexamethasone, reduce dexamethasone dose by 50% due to CYP3A4 interaction 3

Moderately Emetogenic Chemotherapy (MEC)

Acute Phase:

• 5-HT3 antagonist (same options as HEC) 1
• PLUS Dexamethasone 8 mg PO/IV 1
• Consider adding NK1 antagonist for patients with additional risk factors or previous treatment failure 1, 5

Delayed Phase:

• Dexamethasone 8 mg PO once daily (optional) 1

Low Emetogenic Chemotherapy

• Dexamethasone 8 mg PO single dose 1
• No routine delayed prophylaxis needed 1

Minimally Emetogenic Chemotherapy

• No routine antiemetic prophylaxis required 1

Pediatric Dosing

For children receiving highly or moderately emetogenic chemotherapy:

• 5-HT3 antagonist PLUS corticosteroid before chemotherapy 1
• Higher weight-based doses of 5-HT3 antagonists are required compared to adults due to pharmacokinetic differences 1, 6
• The combination of 5-HT3 antagonist plus dexamethasone is superior to 5-HT3 antagonist alone 6

Breakthrough/Refractory Nausea and Vomiting

When nausea/vomiting occurs despite optimal prophylaxis:

1. Re-evaluate: Confirm correct emetic risk classification, check for other causes (bowel obstruction, brain metastases, metabolic disturbances, concurrent medications like opioids) 1, 3

2. Add olanzapine 5-10 mg PO daily if not already given prophylactically 1, 2

3. Add dopamine antagonist to existing regimen 3:

   • Metoclopramide 20-30 mg PO 3-4 times daily 3
   • Prochlorperazine 10-20 mg PO every 6 hours 4, 3, 4
   • Haloperidol 1 mg PO every 4 hours PRN 4

4. Consider adding benzodiazepine:

   • Lorazepam 1-2 mg PO every 1-2 hours PRN 4, 3, 4, 3
   • Alprazolam 1

5. Alternative agents:

   • Promethazine 25-50 mg PR every 6 hours PRN 4
   • Diphenhydramine 50 mg PO every 4-6 hours PRN 4
   • Dronabinol 2.5-7.5 mg PO every 4 hours PRN 4

Use breakthrough medications continuously rather than PRN for better control 7

Anticipatory Nausea and Vomiting

• Lorazepam 1 mg PO at bedtime the night before chemotherapy and 1 mg the morning of chemotherapy 4, 3, 4, 3
• Behavioral modification and biofeedback techniques 4, 3
• Prevention is key: Use the most effective antiemetic regimen from the first chemotherapy cycle 2

Special Situations

High-Dose Chemotherapy with Stem Cell Transplant

• 5-HT3 antagonist PLUS dexamethasone PLUS NK1 antagonist 1, 2
• Consider adding olanzapine as a 4-drug combination 2
• Use full doses intravenously 3

Multiday Chemotherapy Regimens

• Administer antiemetics appropriate for the emetic risk each day of chemotherapy 1
• Continue for 2 days after completion of chemotherapy 1
• For 4-5 day cisplatin regimens: Use 5-HT3 antagonist + dexamethasone + NK1 antagonist 1

Key Clinical Pearls

Route of Administration:

• Oral route is as effective as IV for most antiemetics, even with highly emetogenic chemotherapy 8
• Use IV if patient cannot tolerate oral medications 4

Dosing Principles:

• Single daily dosing is as effective as multiple doses or continuous infusion for 5-HT3 antagonists 8
• There is a plateau effect—higher doses do not improve efficacy 8

Adjunctive Agents:

• Lorazepam and diphenhydramine are useful adjuncts but not recommended as single agents 1, 2
• Consider H2 blockers or proton pump inhibitors for gastric protection 5

Common Pitfalls:

• Underdosing dexamethasone (use 20 mg for HEC, not lower doses)
• Omitting NK1 antagonists for highly emetogenic regimens
• Not adjusting dexamethasone dose when combining with aprepitant
• Using PRN dosing for breakthrough nausea instead of scheduled dosing
• Failing to recognize that anthracycline-cyclophosphamide combinations are now classified as highly emetogenic 1

Drug Interactions:

• Aprepitant is metabolized via CYP3A4—reduce corticosteroid dose by 50% when combined 3
• Rolapitant has extended half-life—do not administer more frequently than every 2 weeks 5

Adverse Effects to Monitor:

• QT prolongation with 5-HT3 antagonists and metoclopramide 9
• Extrapyramidal effects with dopamine antagonists, especially in children 9, 6
• Excessive sedation with benzodiazepines 4